Most Clicked StoriesMore >


Shire accepts AbbVie's $55B takeover bid

BIO SmartBrief | Jul 21, 2014

U.K. drugmaker Shire has accepted AbbVie's takeover offer for about $55 billion in a deal that will allow the U.S. firm to reduce its reliance on arthritis treatment Humira and slash its corporate tax rate by relocating to the U.K. The firms plan to establish a new company that will be incorporated on Jersey and tax-domiciled in Britain. The acquisition is expected to be finalized in the fourth quarter. Reuters (07/19) PMLive.com (U.K.) (07/18) ABC News (07/18)


AstraZeneca, Advaxis agree to combine cancer drugs in clinical trial

BIO SmartBrief | Jul 23, 2014

Feds commit $6.3M to advanced biofuel research

BIO SmartBrief | Jul 18, 2014

U.S. needs new mechanisms to encourage drug development

BIO SmartBrief | Jul 23, 2014

Pancreatic cancer drug combo wins breakthrough status from FDA

BIO SmartBrief | Jul 22, 2014

Report: Ethanol production to increase through 2023

BIO SmartBrief | Jul 22, 2014

Group looks to invest up to $60M in life sciences startups

BIO SmartBrief | Jul 18, 2014

Pulmonary fibrosis drug from InterMune secures FDA breakthrough designation

BIO SmartBrief | Jul 21, 2014

New technology could end malaria by changing mosquito DNA

BIO SmartBrief | Jul 21, 2014

Push for reduced taxes helps drive international pharma deals

BIO SmartBrief | Jul 18, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Faster & better connections with quality R&D vendors

BIO SmartBrief | Jul 24, 2014

Registration is open for the BIO Investor Forum!

BIO SmartBrief | Jul 22, 2014

Announcing the BIO Latin America Conference!

BIO SmartBrief | Jul 21, 2014

Secure document sharing services optimized for life science organizations

BIO SmartBrief | Jul 16, 2014

Spring 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Jul 11, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more